Abstract
This study aims to evaluate plasma osteopontin (OPN) levels as a potential biomarker for hepatocellular carcinoma (HCC). Osteopontin (OPN) is a secreted glycoprotein that is associated with tumorigenesis and metastasis. We measured plasma levels of OPN in 26 HCC patients, 27 patients with chronic liver diseases (CLD), and 15 healthy control individuals using a standardized ELISA kit. The mean plasma OPN level was significantly higher in the HCC group than the CLD group or the normal control group (p-value =0.001/<0.0001). Plasma OPN levels were significantly higher in patients with a tumor size >5 cm in diameter than those with tumors ≤5 cm (p=0.02). OPN levels in the HCC group were not significantly affected by advancing degree of Child-Pugh class. Diagnostic sensitivity and specificity of OPN for HCC were 61% and 82%, respectively (cut-off value: 118.69ng/mL). The area under the ROC curve (AUC) value for OPN was 0.784. However, the AUC value was 0.844 for AFP. The plasma levels of OPN show low diagnostic accuracy for HCC compared to AFP. However, OPN may have a complementary role in diagnosing HCC in patients with non-diagnostic levels of AFP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
